Deepcell Closes $20 Million Series A Round to Develop AI-Powered Capture of Cells for Precision Medicine
Summary
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Deepcell, a life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, today announced that it has closed its Series A round of financing with $20 million, led by Bow Capital and joined by Andreessen Horowitz, which led its $5 million seed round. Spun out of Stanford University in 2017, Deepcell is using deep learning and big data to classify and isolate individual cells from a sample. “By taking cell morphology into the digital age, Deepcell has the potential to revolutionize the field, in a similar way that high-performance computing enabled dramatic advances in genomics and transcriptomics,” said Vijay Pande, General Partner at Andreessen Horowitz. Maddison Masaeli, co-founder and CEO of Deepcell, commented: “Cell morphology is a phenotype with a long history in clinical application that has to date been based on the eyes of a human expert. Spun out of Stanford University in 2017, the company has created unique, microfluidics-based technology that uses continuously learning AI to classify cells based on detailed visual features and sort them without inherent bias.
Funding
Review available funding amount, funding date, investors, and linked company information related to Deepcell Closes $20 Million Series A Round to Develop AI-Powered Capture of Cells for Precision Medicine in the interactive ISVWorld profile.